Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 26,944 full-time employees. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. The company works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
The most recent EPS for Dr. Reddy's Laboratories Limited is $5.73, beating expectations of $11.4.
How did Dr. Reddy's Laboratories Limited RDY's revenue perform in the last quarter?
Dr. Reddy's Laboratories Limited revenue for the last quarter is $5.73
What is the revenue estimate for Dr. Reddy's Laboratories Limited?
According to 3 of Wall street analyst, the revenue estimate of Dr. Reddy's Laboratories Limited range from $84.97B to $79.3B
What's the earning quality score for Dr. Reddy's Laboratories Limited?
Dr. Reddy's Laboratories Limited has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Dr. Reddy's Laboratories Limited report earnings?
Dr. Reddy's Laboratories Limited next earnings report is expected in 2026-08-10
What are Dr. Reddy's Laboratories Limited's expected earnings?
Dr. Reddy's Laboratories Limited expected earnings is $84.1B, according to wall-street analysts.
Did Dr. Reddy's Laboratories Limited beat earnings expectations?
Dr. Reddy's Laboratories Limited recent earnings of $76.6B does not beat expectations.